Cargando…

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor

No approved therapy exists for cancer‐associated cachexia. The colon‐26 mouse model of cancer cachexia mimics recent late‐stage clinical failures of anabolic anti‐cachexia therapy and was unresponsive to anabolic doses of diverse androgens, including the selective androgen receptor modulator (SARM)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liva, Sophia G, Tseng, Yu‐Chou, Dauki, Anees M, Sovic, Michael G, Vu, Trang, Henderson, Sally E, Kuo, Yi‐Chiu, Benedict, Jason A, Zhang, Xiaoli, Remaily, Bryan C, Kulp, Samuel K, Campbell, Moray, Bekaii‐Saab, Tanios, Phelps, Mitchell A, Chen, Ching‐Shih, Coss, Christopher C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005646/ https://www.ncbi.nlm.nih.gov/pubmed/31930715 http://dx.doi.org/10.15252/emmm.201809910

Ejemplares similares

Murine cancer cachexia models replicate elevated catabolic pembrolizumab clearance in humans
por: Castillo, Alyssa Marie M., et al.
Publicado: (2021)

New developments in the treatment of metastatic gastric cancer: focus on trastuzumab
por: Rose, Jeffrey S, et al.
Publicado: (2011)

CpG Island Methylation, Microsatellite Instability, and BRAF Mutations and Their Clinical Application in the Treatment of Colon Cancer
por: Wu, Christina, et al.
Publicado: (2012)

Update to “Homologous Recombination Repair Defect May Predict Treatment Response to Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors”
por: Zhu, Mojun, et al.
Publicado: (2022)

SAT021 Development Of Niclosamide Analogs For Treatment Of Androgen Receptor Positive Hepatocellular Carcinoma
por: Jordan Montgomery, Emma, et al.
Publicado: (2023)

Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers: What Is the Role of Novel Oral Anticoagulants?
por: Martin, Ludmila Katherine, et al.
Publicado: (2012)

The Continued Promise and Many Disappointments of Oncolytic Virotherapy in Gastrointestinal Malignancies
por: Ahn, Daniel H., et al.
Publicado: (2017)

Response to Drs Von Hoff and Renschler
por: Ahn, Daniel H., et al.
Publicado: (2017)

Identifying and targeting cancer stem cells in the treatment of gastric cancer
por: Bekaii‐Saab, Tanios, et al.
Publicado: (2017)

Cancer cachexia and anabolic interventions: a case report
por: Dillon, Edgar L., et al.
Publicado: (2012)

Pemigatinib for adults with previously treated, locally advanced or metastatic cholangiocarcinoma with FGFR2 fusions/rearrangements
por: Walden, Daniel, et al.
Publicado: (2022)

Social Media, Body Image and Resistance Training: Creating the Perfect ‘Me’ with Dietary Supplements, Anabolic Steroids and SARM’s
por: Hilkens, Luuk, et al.
Publicado: (2021)

Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives
por: Bupathi, Manojkumar, et al.
Publicado: (2016)

Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42()()
por: Henderson, Sally E., et al.
Publicado: (2016)

Emerging Therapies and Future Directions in Targeting the Tumor Stroma and Immune System in the Treatment of Pancreatic Adenocarcinoma
por: Ahn, Daniel H., et al.
Publicado: (2018)

Therapeutic Targeting Strategies of Cancer Stem Cells in Gastrointestinal Malignancies
por: Sonbol, Mohamad B., et al.
Publicado: (2019)

Frontline therapy for advanced hepatocellular carcinoma: an update
por: Akce, Mehmet, et al.
Publicado: (2022)

SARM1 detection in myelinating glia: sarm1/Sarm1 is dispensable for PNS and CNS myelination in zebrafish and mice
por: Fazal, Shaline V., et al.
Publicado: (2023)

Skeletal muscle anabolism is a side effect of therapy with the MEK inhibitor: selumetinib in patients with cholangiocarcinoma
por: Prado, C M M, et al.
Publicado: (2012)

Population Pharmacokinetic Analysis from First-in-Human Data for HDAC Inhibitor, REC-2282 (AR-42), in Patients with Solid Tumors and Hematologic Malignancies: A Case Study for Evaluating Flat vs. Body Size Normalized Dosing
por: Liva, Sophia, et al.
Publicado: (2021)

Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: A case report
por: So, Brian J, et al.
Publicado: (2008)

Linking Cancer Cachexia-Induced Anabolic Resistance to Skeletal Muscle Oxidative Metabolism
por: Hardee, Justin P., et al.
Publicado: (2017)

How to Overcome Anabolic Resistance in Dialysis-Treated Patients?
por: Garibotto, Giacomo, et al.
Publicado: (2021)

A novel mutation in the tyrosine kinase domain of ERBB2 in hepatocellular carcinoma
por: Bekaii-Saab, Tanios, et al.
Publicado: (2006)

Necroptosis is SARMful to your health
por: Pierchala, Brian A.
Publicado: (2020)

Immunogenicity and antitumor efficacy of a novel human PD-1 B-cell vaccine (PD1-Vaxx) and combination immunotherapy with dual trastuzumab/pertuzumab-like HER-2 B-cell epitope vaccines (B-Vaxx) in a syngeneic mouse model
por: Kaumaya, Pravin T. P., et al.
Publicado: (2020)

CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128
por: Badawi, Mohamed, et al.
Publicado: (2018)

Adjuvant therapy for pancreas cancer in an era of value based cancer care
por: Ahn, Daniel H., et al.
Publicado: (2015)

Genetically engineered murine pancreatic cancer models approximate immunophenotypic properties of human patients
por: Mace, Thomas A, et al.
Publicado: (2013)

Results of an abbreviated phase-II study with the Akt Inhibitor MK-2206 in Patients with Advanced Biliary Cancer
por: Ahn, Daniel H., et al.
Publicado: (2015)

Whole-exome tumor sequencing study in biliary cancer patients with a response to MEK inhibitors
por: Ahn, Daniel H., et al.
Publicado: (2015)

Altered Plasma Fatty Acid Abundance Is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer
por: Gumpper-Fedus, Kristyn, et al.
Publicado: (2022)

Small Molecule SARM1 Inhibitors Recapitulate the SARM1(−/−) Phenotype and Allow Recovery of a Metastable Pool of Axons Fated to Degenerate
por: Hughes, Robert O., et al.
Publicado: (2021)

Sarm1 is dispensable for mechanosensory-motor transformations in zebrafish
por: Asgharsharghi, Amir, et al.
Publicado: (2021)

Multifaceted roles of SARM1 in axon degeneration and signaling
por: Waller, Thomas J., et al.
Publicado: (2022)

Poster 390: Systematic Review of SARMs Abuse in Athletes
por: Hahamyan, Henrik, et al.
Publicado: (2023)

Anabolic and Pro-metabolic Functions of CREB-CRTC in Skeletal Muscle: Advantages and Obstacles for Type 2 Diabetes and Cancer Cachexia
por: Berdeaux, Rebecca, et al.
Publicado: (2019)

Using Naïve Bayesian Analysis to Determine Imaging Characteristics of KRAS Mutations in Metastatic Colon Cancer
por: Pershad, Yash, et al.
Publicado: (2017)

Impact of Tumor Location and Variables Associated With Overall Survival in Patients With Colorectal Cancer: A Mayo Clinic Colon and Rectal Cancer Registry Study
por: Wang, Cassia B., et al.
Publicado: (2019)

Maintenance Therapy in First-Line Gastric and Gastroesophageal Junction Adenocarcinoma: A Retrospective Analysis
por: Walden, Daniel, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gn8u3crjrds91lifb1ed7dkjmd